StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a report issued on Thursday.
Several other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed a neutral rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. The Goldman Sachs Group increased their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a report on Tuesday, June 4th. Finally, Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an outperform rating in a research report on Tuesday, June 4th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $50.67.
View Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Stock Performance
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to the consensus estimate of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. The company’s revenue was up 46.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.47) earnings per share. On average, equities analysts expect that Agios Pharmaceuticals will post -2.68 EPS for the current year.
Institutional Investors Weigh In On Agios Pharmaceuticals
A number of hedge funds have recently modified their holdings of AGIO. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $41,000. China Universal Asset Management Co. Ltd. increased its position in Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 5,040 shares during the last quarter. NEOS Investment Management LLC acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $210,000. Entropy Technologies LP acquired a new stake in Agios Pharmaceuticals during the first quarter worth about $286,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 942 shares during the last quarter.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
- Five stocks we like better than Agios Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- Top 3 Defense Stocks That Should Be on Your Radar
- Investing In Preferred Stock vs. Common Stock
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.